Monte Rosa Therapeutics Inc (GLUE) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Monte Rosa Therapeutics Inc stock $7.16, price $9.16, that is 21.8% below the price, quality 45 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Monte Rosa Therapeutics Inc
GLUE · USExpensive (fair value 22% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $2.50 – $42.21 · fair‑value band $5.37 – $8.95 · the $9.16 price screens above the $7.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Monte Rosa Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
Show moreShow less
The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases.
The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis.
The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Stock analysis
Monte Rosa Therapeutics Inc (GLUE) currently trades at $9.16, while our estimate is $7.16, 22% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $5.37 (bear) to $8.95 (bull), the price of $9.16 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Monte Rosa Therapeutics Inc reported revenue of $124M in FY2025 versus $0 in FY2021. Reported net income was −$38.6M in FY2025.
Key figures
Market cap $803M Small · P/S ratio 12.9 · EPS (TTM) $−1.39 · Net margin −31.2% · Return on equity −35.3% · Return on assets (EBIT) −26.1% (5-year average) · Operating margin −3.6% · Revenue (TTM) $70.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 64% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −22%, GLUE screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 6 officers or directors sold shares worth $2.5M and none bought.
- SaleMatthew BowenPrincipal Accounting Officer13 shares at $10.56$137Oct 5, 2026
- SaleMarkus WarmuthPresident & CEO, Director7× since Jan 5, 2026: 49,500 shares, avg. $19.21$951,078Jul 16, 2026
- SaleJennifer ChampouxChief Operating Officer6× since Jan 5, 2026: 15,682 shares, avg. $19.85$311,296Jul 15, 2026
- SaleSharon TownsonChief Scientific Officer5× since Jan 5, 2026: 21,155 shares, avg. $20.04$423,933Jul 6, 2026
- SaleFilip JankuChief Medical Officer5× since Jan 5, 2026: 65,596 shares, avg. $21.03$1.4MJun 30, 2026
- SaleAnthony M. ManningDirector2× since May 21, 2026: 20,000 shares, avg. $20.56$411,200Jun 29, 2026
- SalePhilip NicksonChief Business & Legal Officer2× since Jan 5, 2026: 9,000 shares, avg. $16.81$151,259Apr 9, 2026
- SaleEdmund DunnPrincipal Accounting Officer3× since Jan 5, 2026: 26,878 shares, avg. $17.97$483,106Mar 4, 2026
Plus 15 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Earlier news
- Monte Rosa Therapeutics (GLUE) Tops Q3 Earnings and Revenue Estimates
- Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
- Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular
Compare Monte Rosa Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs GLUE |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs GLUE |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs GLUE |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs GLUE |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs GLUE |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs GLUE |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs GLUE |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs GLUE |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs GLUE |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs GLUE |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Monte Rosa Therapeutics Inc (GLUE) overvalued or undervalued?
What is the fair value of GLUE?
What is the quality score of GLUE?
What is the price target for Monte Rosa Therapeutics Inc (GLUE)?
What is the Monte Rosa Therapeutics Inc stock forecast for 2026?
What is the revenue of Monte Rosa Therapeutics Inc (GLUE)?
What is the intrinsic value of Monte Rosa Therapeutics Inc (GLUE)?
Is Monte Rosa Therapeutics Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of GLUE?
How much is Monte Rosa Therapeutics Inc worth?
What do the bullish and bearish scenarios say about GLUE?
How solid is the balance sheet of Monte Rosa Therapeutics Inc (GLUE)?
How far is GLUE from its 52-week high?
Which stocks are comparable to Monte Rosa Therapeutics Inc?
Is Monte Rosa Therapeutics Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Monte Rosa Therapeutics Inc (GLUE)?
What should I pay attention to with Monte Rosa Therapeutics Inc right now?
Key figures of Monte Rosa Therapeutics Inc
How large is the market capitalisation of Monte Rosa Therapeutics Inc (GLUE)?
What is the P/S ratio of Monte Rosa Therapeutics Inc (GLUE)?
What are the earnings per share of Monte Rosa Therapeutics Inc (GLUE)?
What is the net margin of Monte Rosa Therapeutics Inc (GLUE)?
What is the return on equity of Monte Rosa Therapeutics Inc (GLUE)?
What is the EBIT return on assets of Monte Rosa Therapeutics Inc (GLUE)?
What is the operating margin of Monte Rosa Therapeutics Inc (GLUE)?
How fast is revenue growing at Monte Rosa Therapeutics Inc (GLUE)?
How much free cash flow does Monte Rosa Therapeutics Inc (GLUE) generate?
How much net cash does Monte Rosa Therapeutics Inc (GLUE) hold?
Watch Monte Rosa Therapeutics Inc in the live analysis
One click puts Monte Rosa Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.